Who is sponsoring NCT03420105?

NCT03420105 is sponsored by Centre Francois Baclesse.

What condition does NCT03420105 study?

NCT03420105 studies Breast Cancer, Memory Disorders.

Is NCT03420105 still recruiting?

NCT03420105 is currently completed. Last updated 9 March 2020.

Last reviewed 2020-03-09 · How we verify

NCT03420105: PROSOM-K

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of the Functioning of Prospective Memory in Breast Cancer and the Influence of Sleep

Completed NA Last updated 9 March 2020

What this trial tests

NA trial testing Neuropsychological, psycho-pathological and quality of life assessments in Breast Cancer in 75 participants. Completed in 6 March 2020.

Timeline

5 January 2018

Primary endpoint
6 March 2020

6 March 2020

Quick facts

Lead sponsor	Centre Francois Baclesse
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	75
Start date	5 January 2018
Primary completion	6 March 2020
Estimated completion	6 March 2020
Sites	2 locations across France

Drugs / interventions tested

Neuropsychological, psycho-pathological and quality of life assessments
Hormonotherapy — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Memory Disorders — all drugs for Memory Disorders →

Sponsor

Centre Francois Baclesse — full company profile →

Who can join

Adults 18 to 70, female only, with Breast Cancer or Memory Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The results of this study will contribute to a better understanding of prospective memory deficit processes in breast cancer in relation to sleep disorders frequently reported in this pathology. In the long term, a better understanding will make it possible to envisage appropriate treatments to compensate for these memory difficulties and to improve the autonomy of the patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Impact of breast cancer on prospective memory functioning assessed by virtual reality and influence of sleep quality and hormonal therapy: PROSOM-K study.
Duivon M, Perrier J, Joly F, Licaj I, et al · · 2018 · cited 7× · PMID 30176833 · DOI 10.1186/s12885-018-4762-2
Links between nocturnal hypoxia and cognitive function in breast cancer.
Elia C, Perrier J, Duivon M, Rehel S, et al · · 2025 · PMID 41309988 · DOI 10.1038/s41598-025-26591-z
Links between nocturnal hypoxia and cognitive function in breast cancer
Elia C, Perrier J, Duivon M, Rehel S, et al · · 2025 · DOI 10.21203/rs.3.rs-6016528/v1

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Centre Francois Baclesse trials

Trials by the same sponsor.

NCT06959810 — Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management · NA · recruiting
NCT06792721 — MEASUREMENT OF CIRCULATING MUTATION BURDEN · recruiting
NCT06817161 — Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovar · Phase 3 · recruiting
NCT06612827 — Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions · recruiting
NCT06798922 — Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03420105 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Francois Baclesse
Last refreshed: 9 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03420105.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing